Immune suppression and immune activation in depression

Brain, Behavior, and Immunity

Volumn 25, Issue 2, 2011, Pages 221-229

  Blume, Joshua ^a   Douglas, Steven D ^a,b   Evans, Dwight L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cytokine; Depression; Immune activation; Immune suppression; Immunity; Inflammation; Natural killer cell; T lymphocyte

Indexed keywords

INTERLEUKIN 6;

CHRONIC INFLAMMATION; COMORBIDITY; DEPRESSION; GENE; HUMAN; IMMUNOREGULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; REVIEW;

CYTOKINES; DEPRESSIVE DISORDER; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; T-LYMPHOCYTES;

EID: 78651417057     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.10.008     Document Type: Review

References (122)

1. Aisen P.S., Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiatry 1994, 151:1105-1113.
2. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., Mohebbi-Rasa S., Raznahan M., Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 2009, 26:607-611.
3. Alesci S., Martinez P.E., Kelkar S., Ilias I., Ronsaville D.S., Listwak S.J., Ayala A.R., Licinio J., Gold H.K., Kling M.A., Chrousos G.P., Gold P.W. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab. 2005, 90:2522-2530.
4. Anisman H., Merali Z., Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog. Neurobiol. 2008, 85:1-74.
5. Anisman H., Ravindran A.V., Griffiths J., Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry 1999, 4:182-188.
6. Arbelaez J.J., Ariyo A.A., Crum R.M., Fried L.P., Ford D.E. Depressive symptoms, inflammation, and ischemic stroke in older adults: a prospective analysis in the cardiovascular health study. J. Am. Geriatr. Soc. 2007, 55:1825-1830.
7. Avitsur R., Stark J.L., Sheridan J.F. Social stress induces glucocorticoid resistance in subordinate animals. Horm. Behav. 2001, 39:247-257.
8. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer Biol. 2006, 16:80-88.
9. Benedetti F., Lucca A., Brambilla F., Colombo C., Smeraldi E. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1167-1170.
10. Benton, T., Lynch, K., Dubé, B., Gettes, D., Tustin, N., Lai, J., Metzger, D., Blume, J., Douglas, S., Evans, D., in press. Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. Psychosom. Med.
11. Berg L., Lampa J., Rogberg S., van Vollenhoven R., Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann. Rheum. Dis. 2001, 60:133-139.
12. Blume, J., Benton, T., Lynch, K., Dube, B., Gettes, D., Flanagan, D., Collins, K., Brown, T., Brown, D., Lai, J.P., Metzger, D.S., Douglas, S.D., Evans, D.L., 2010. Depression increases-and citalopram decreases-T-cell HIV infectivity in women ex-vivo (abstract). In: Society of Biological Psychiatry 65th Annual Meeting, New Orleans, LA, May 20-22, 2010 (Abstract No. 401).
13. Bruce T.O. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr. Psychiatry Rep. 2008, 10:258-264.
14. Capuron L., Bluthe R.M., Dantzer R. Cytokines in clinical psychiatry. Am. J. Psychiatry 2001, 158:1163-1164.
15. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
16. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
17. Capuron L., Ravaud A., Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J. Clin. Oncol. 2000, 18:2143-2151.
18. Cardone J., Le Friec G., Vantourout P., Roberts A., Fuchs A., Jackson I., Suddason T., Lord G., Atkinson J.P., Cope A., Hayday A., Kemper C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 2010, 11:862-871.
19. Carney R.M., Freedland K.E. Treatment-resistant depression and mortality after acute coronary syndrome. Am. J. Psychiatry 2009, 166:410-417.
20. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995, 332:1351-1363.
21. Clark J., Vagenas P., Panesar M., Cope A.P. What does tumour necrosis factor excess do to the immune system long term?. Ann. Rheum. Dis. 2005, 64:70-76.
22. Cope A.P. Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology (Oxford) 2003, 42:716-731.
23. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
24. Cruess D.G., Douglas S.D., Petitto J.M., Have T.T., Gettes D., Dube B., Cary M., Evans D.L. Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am. J. Psychiatry 2005, 162:2125-2130.
25. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. N.Y. Acad. Sci. 2001, 933:222-234.
26. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
27. Dantzer R., Wollman E., Vitkovic L., Yirmiya R. Cytokines and depression: fortuitous or causative association?. Mol. Psychiatry 1999, 4:328-332.
28. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002, 46:2287-2293.
29. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
30. + natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in haemodialysis patients. Nephrology 2009, 14:471-475.
31. + natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif. 2008, 26:317-321.
32. Evans D.L., Charney D.S., Lewis L., Golden R.N., Gorman J.M., Krishnan K.R., Nemeroff C.B., Bremner J.D., Carney R.M., Coyne J.C., Delong M.R., Frasure-Smith N., Glassman A.H., Gold P.W., Grant I., Gwyther L., Ironson G., Johnson R.L., Kanner A.M., Katon W.J., Kaufmann P.G., Keefe F.J., Ketter T., Laughren T.P., Leserman J., Lyketsos C.G., McDonald W.M., McEwen B.S., Miller A.H., Musselman D., O'Connor C., Petitto J.M., Pollock B.G., Robinson R.G., Roose S.P., Rowland J., Sheline Y., Sheps D.S., Simon G., Spiegel D., Stunkard A., Sunderland T., Tibbits P., Valvo W.J. Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry 2005, 58:175-189.
33. Evans D.L., Folds J.D., Petitto J.M., Golden R.N., Pedersen C.A., Corrigan M., Gilmore J.H., Silva S.G., Quade D., Ozer H. Circulating natural killer cell phenotypes in men and women with major depression. Relation to cytotoxic activity and severity of depression. Arch. Gen. Psychiatry 1992, 49:388-395.
34. Evans D.L., Lynch K.G., Benton T., Dube B., Gettes D.R., Tustin N.B., Lai J.P., Metzger D., Douglas S.D. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol. Psychiatry 2008, 63:899-905.
35. Evans D.L., Nemeroff C.B. The clinical use of the dexamethasone suppression test in DSM-III affective disorders: correlation with the severe depressive subtypes of melancholia and psychosis. J. Psychiatr. Res. 1987, 21:185-194.
36. Evans D.L., Ten Have T.R., Douglas S.D., Gettes D.R., Morrison M., Chiappini M.S., Brinker-Spence P., Job C., Mercer D.E., Wang Y.L., Cruess D., Dube B., Dalen E.A., Brown T., Bauer R., Petitto J.M. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am. J. Psychiatry 2002, 159:1752-1759.
37. Frank M.G., Wieseler Frank J.L., Hendricks S.E., Burke W.J., Johnson D.R. Age at onset of major depressive disorder predicts reductions in NK cell number and activity. J. Affect. Disord. 2002, 71:159-167.
38. Frank M.G., Miguel Z.D., Watkins L.R., Maier S.F. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav. Immun. 2010, 24:19-30.
39. Frasure-Smith N., Lesperance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch. Gen. Psychiatry 2008, 65:62-71.
40. Frasure-Smith N., Lespérance F., Irwin M.R., Sauvé C., Lespérancel J., Théroux P. Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes. Biol. Psychiatry. 2007, 62:302-308.
41. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., Kelley K.W., Dantzer R., Castanon N. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
42. Glaser R., Kiecolt-Glaser J.K. Stress-associated immune modulation: relevance to viral infections and chronic fatigue syndrome. Am. J. Med. 1998, 105:35S-42S.
43. Grau A.J. Infection, inflammation, and cerebrovascular ischemia. Neurology 1997, 49:S47-S51.
44. Hansson G.K. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
45. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
46. Insel T.R., Fenton W.S. Psychiatric epidemiology: it's not just about counting anymore. Arch. Gen. Psychiatry 2005, 62:590-592.
47. Insel T.R. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch. Gen. Psychiatry 2009, 66:128-133.
48. Irwin M.R., Miller A.H. Depressive disorders and immunity: 20years of progress and discovery. Brain Behav. Immun. 2007, 21:374-383.
49. Jeanmonod P., von Kanel R., Maly F.E., Fischer J.E. Elevated plasma C-reactive protein in chronically distressed subjects who carry the A allele of the TNF-alpha-308 G/A polymorphism. Psychosom. Med. 2004, 66:501-506.
50. Kaestner F., Hettich M., Peters M., Sibrowski W., Hetzel G., Ponath G., Arolt V., Cassens U., Rothermundt M. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 2005, 87:305-311.
51. Kendell R., Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am. J. Psychiatry 2003, 160:4-12.
52. Kiecolt-Glaser J.K., Glaser R. Depression and immune function: central pathways to morbidity and mortality. J. Psychosom. Res. 2002, 53:873-876.
53. Kiecolt-Glaser J.K., Glaser R., Gravenstein S., Marlarkey W.B., Sheridan J. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3043-3047.
54. Kiecolt-Glaser J.K., Preacher K.J., MacCallum R.C., Atkinson C., Malarkey W.B., Galser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:9090-9095.
55. Kling M.A., Alesci S., Csako G., Costello R., Luckenbaugh D.A., Bonne O., Duncko R., Drevets W.C., Manji H.K., Charney D.S., Gold P.W., Neumeister A. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol. Psychiatry 2007, 62:309-313.
56. Kronfol Z., House J.D., Silva J., Greden J., Carroll B.J. Depression, urinary free cortisol excretion and lymphocyte function. Br. J. Psychiatry 1986, 148:70-73.
57. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
58. Leserman J., Petitto J.M., Golden R.N., Gaynes B.N., Gu H., Perkins D.O., Silva S.G., Folds J.D., Evans D.L. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am. J. Psychiatry 2000, 157:1221-1228.
59. Leserman J., Petitto J.M., Gu H., Gaynes B.N., Barroso J., Golden R.N., Perkins D.O., Folds J.D., Evans D.L. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol. Med. 2002, 32:1059-1073.
60. Leserman J., Petitto J.M., Perkins D.O., Folds J.D., Golden R.N., Evans D.L. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Arch. Gen. Psychiatry 1997, 54:279-285.
61. Lowy M.T., Reder A.T., Antel J.P., Meltzer H.Y. Glucocorticoid resistance in depression: the dexamethasone suppression test and lymphocyte sensitivity to dexamethasone. Am. J. Psychiatry 1984, 141:1365-1370.
62. Lowy M.T., Reder A.T., Gormley G.J., Meltzer H.Y. Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the dexamethasone suppression test. Biol. Psychiatry 1988, 24:619-630.
63. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
64. Maes M., Bosmans E., Suy E., Minner B., Raus J. A further exploration of the relationships between immune parameters and the HPA-axis activity in depressed patients. Psychol. Med. 1991, 21:313-320.
65. Matsunaga M., Isowa T., Murakami H., Kasugai K., Yoneda M., Kaneko H., Ohira H. Association of polymorphism in the human mu-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception. Brain Behav. Immun. 2009, 23:931-935.
66. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
67. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 2006, 21:227-231.
68. 2: antidepressant and gender effects on responding for " free chow" and " earned" sucrose intake. Psychopharmacology (Berlin) 2003, 165:413-418.
69. Miller A.H. Depression and immunity: a role for T cells?. Brain Behav. Immun. 2010, 24:1-8.
70. Miller A.H. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav. Immun. 2009, 23:149-158.
71. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
72. Miller G.E., Chen E., Sze J., Marin T., Arevalo J.M.G., Doll R., Ma R., Cole S.W. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-κB signaling. Biol. Psychiatry 2008, 64:266-272.
73. Miller G.E., Cohen S., Herbert T.B. Pathways linking major depression and immunity in ambulatory female patients. Psychosom. Med. 1999, 61:850-860.
74. Moraska A., Campisi J., Nguyen K.T., Maier S.F., Watkins L.R., Fleshner M. Elevated IL-1beta contributes to antibody suppression produced by stress. J. Appl. Physiol. 2002, 93:207-215.
75. Moreau M., Lestage J., Verrier D., Mormede C., Kelley K.W., Dantzer R., Castanon N. Bacille Calmette-Guerin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice. J. Infect. Dis. 2005, 192:537-544.
76. Mossner R., Lesch K.P. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun. 1998, 12:249-271.
77. Muller A.J., Sharma M.D., Chandler P.R., Duhadaway J.B., Everhart M.E., Johnson B.A., Kahler D.J., Pihkala J., Soler A.P., Munn D.H., Prendergast G.C., Mellor A.L. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. USA 2008, 105:17073-17078.
78. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
79. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11:680-684.
80. Myint A., Kim Y.K., Verkerk R., Scharpé S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007, 98:143-151.
81. Nelson J.C., Davis J.M. DST studies in psychotic depression: a meta-analysis. Am. J. Psychiatry 1997, 154:1497-1503.
82. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 1988, 45:577-579.
83. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
84. O'Connor J.C., Lawson M.A., Andre C., Briley E.M., Szegedi S.S., Lestage J., Castanon N., Herkenham M., Dantzer R., Kelley K.W. Induction of IDO by Bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J. Immunol. 2009, 182:3202-3212.
85. Pariante C.M. Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004, 7:209-219.
86. Pariante C.M., Makoff A., Lovestone S., Feroli S., Heyden A., Miller A.H., Kerwin R.W. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br. J. Pharmacol. 2001, 134:1335-1343.
87. Pariante C.M., Pearce B.D., Pisell T.L., Sanchez C.I., Po C., Su C., Miller A.H. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 1999, 140:4359-4366.
88. Petitto J.M., Folds J.D., Evans D.L. Abnormal diurnal variation of B lymphocyte circulation patterns in major depression. Biol. Psychiatry 1993, 34:268-270.
89. Petitto J.M., Folds J.D., Ozer H., Quade D., Evans D.L. Abnormal diurnal variation in circulating natural killer cell phenotypes and cytotoxic activity in major depression. Am. J. Psychiatry 1992, 149:694-696.
90. Pike J.L., Irwin M.R. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav. Immun. 2006, 20:169-174.
91. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-[alpha] effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry 2010, 15:535-547.
92. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
93. Raison C.L., Broadwell S.D., Borisov A.S., Manatunga A.K., Capuron L., Woolwine B.J., Jacobson I.M., Nemeroff C.B., Miller A.H. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav. Immun. 2005, 19:23-27.
94. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
95. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160:1554-1565.
96. Ridker P.M., Danielson E., Fonseca F., Genest J., Gotto A.M., Kastelein J., Koenig W., Libby P., Lorenzatti A., MacFadyen J., Nordestgaard B., Shepherd J., Willerson J., Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359:2195-2207. the JUPITER Study Group.
97. Rohleder N., Miller G.E. Acute deviations from long-term trait depressive symptoms predict systemic inflammatory activity. Brain Behav. Immun. 2008, 22:709-716.
98. Rothermundt M., Arolt V., Peters M., Gutbrodt H., Fenker J., Kersting A., Kirchner H. Inflammatory markers in major depression and melancholia. J. Affect. Disord. 2001, 63:93-102.
99. Roybal K.T., Wulfing C. Inhibiting the inhibitor of the inhibitor: blocking PKC-{theta} to enhance regulatory T cell function. Sci. Signal. 2010, 3:pe24.
100. Scherrer J.F., Xian H., Bucholz K.K., Eisen S.A., Lyons M.J., Goldberg J., Tsuang M.D.S., True W.R. A twin study of depression symptoms, hypertension, and heart disease in middle-aged men. Psychosom. Med. 2003, 65:548-557.
101. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
102. Sorrells S.F., Sapolsky R.M. Glucocorticoids can arm macrophages for innate immune battle. Brain Behav. Immun. 2010, 24:17-18.
103. Sorrells S.F., Sapolsky R.M. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav. Immun. 2007, 21:259-272.
104. Sothern R.B., Roitman-Johnson B., Kanabrocki E.L., Yager J.G., Roodell M.M., Weatherbee J.A., Young M.R., Nemchausky B.M., Scheving L.E. Circadian characteristics of circulating interleukin-6 in men. J. Allergy Clin. Immunol. 1995, 95:1029-1035.
105. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 2003, 54:269-282.
106. Spitzer R.L., Endicott J., Williams J.B.W. Research diagnostic criteria. Arch. Gen. Psychiatry 1979, 36:1381-1382.
107. Stark J.L., Avitsur R., Hunzeker J., Padgett D.A., Sheridan J.F. Interleukin-6 and the development of social disruption-induced glucocorticoid resistance. J. Neuroimmunol. 2002, 124:9-15.
108. Su S., Miller A.H., Snieder H., Bremner J.D., Ritchie J., Maisano C., Jones L., Murrah N.V., Goldberg J., Vaccarino V. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom. Med. 2009, 71:152-158.
109. Turnbull A.V., Rivier C. Regulation of the HPA axis by cytokines. Brain Behav. Immun. 1995, 9:253-275.
110. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
111. Vaccarino V., Brennan M.L., Miller A.H., Bremner J.D., Ritchie J.C., Lindau F., Veledar E., Su S., Murrah N.V., Jones L., Jawed F., Dai J., Goldberg J., Hazen S.L. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol. Psychiatry 2008, 64:476-483.
112. Vaknin I., Blinder L., Wang L., Gazit R., Shapira E., Genina O., Pines M., Pikarsky E., Baniyash M. A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood 2008, 111:1437-1447.
113. Van Lieshout R.J., Bienenstock J., MacQueen G.M. A review of candidate pathways underlying the association between asthma and major depressive disorder. Psychosom. Med. 2009, 71:187-195.
114. van Praag H.M. Diagnosis, the rate-limiting factor of biological depression research. Neuropsychobiology 1993, 28:197-206.
115. Vaughan C.J. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am. J. Cardiol. 2003, 91:23B-29B.
116. Whooley M.A., Caska C.M., Hendrickson B.E., Rourke M.A., Ho J., Ali S. Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol. Psychiatry 2007, 62:314-320.
117. Wijeratne C., Sachdev P. Treatment-resistant depression: critique of current approaches. Aust. N.Z.J. Psychiatry 2008, 42:751-762.
118. World Health Organization, 2008. The Global Burden of Disease: 2004 Update, 153.
119. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
120. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996, 711:163-174.
121. Zanin-Zhorov A., Ding Y., Kumari S., Attur M., Hippen K.L., Brown M., Blazar B.R., Abramson S.B., Lafaille J.J., Dustin M.L. Protein kinase C-{theta} mediates negative feedback on regulatory T cell function. Science 2010, 328:372-376.
122. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., Schmidt K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 2001, 15:199-226.